|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size 8/05/15 Opko Health, Inc. 10-Q 6/30/15 80:10M |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 654K
2: EX-2.1 Plan of Acquisition, Reorganization, Arrangement, HTML 185K
Liquidation or Succession
3: EX-2.2 Plan of Acquisition, Reorganization, Arrangement, HTML 114K
Liquidation or Succession
4: EX-31.1 Certification -- §302 - SOA'02 HTML 30K
5: EX-31.2 Certification -- §302 - SOA'02 HTML 30K
6: EX-32.1 Certification -- §906 - SOA'02 HTML 24K
7: EX-32.2 Certification -- §906 - SOA'02 HTML 25K
54: R1 Document and Entity Information HTML 42K
42: R2 Condensed Consolidated Balance Sheets (Unaudited) HTML 111K
52: R3 Condensed Consolidated Balance Sheets (Unaudited) HTML 38K
(Parenthetical)
56: R4 Condensed Consolidated Statements of Operations HTML 96K
(Unaudited)
74: R5 Condensed Consolidated Statements of Comprehensive HTML 51K
Loss (Unaudited)
45: R6 Condensed Consolidated Statements of Cash Flows HTML 168K
(Unaudited)
51: R7 Condensed Consolidated Statements of Cash Flows HTML 26K
(Unaudited) (Parenthetical)
38: R8 Business and Organization HTML 34K
29: R9 Summary of Significant Accounting Policies HTML 66K
75: R10 Loss Per Share HTML 32K
58: R11 Composition of Certain Financial Statement HTML 130K
Captions
57: R12 Acquisitions, Investments, and Licenses HTML 126K
63: R13 Debt HTML 109K
64: R14 Accumulated Other Comprehensive Income (Loss) HTML 44K
61: R15 Fair Value Measurements HTML 179K
65: R16 Derivative Contracts HTML 101K
53: R17 Related Party Transactions HTML 40K
55: R18 Commitments and Contingencies HTML 39K
60: R19 Strategic Alliances HTML 41K
80: R20 Segments HTML 164K
70: R21 Subsequent Events HTML 29K
48: R22 Summary of Significant Accounting Policies HTML 122K
(Policies)
59: R23 Composition of Certain Financial Statement HTML 131K
Captions (Tables)
50: R24 Acquisitions, Investments, and Licenses (Tables) HTML 103K
22: R25 Debt (Tables) HTML 100K
71: R26 Accumulated Other Comprehensive Income (Loss) HTML 40K
(Tables)
77: R27 Fair Value Measurements (Tables) HTML 176K
33: R28 Derivative Contracts (Tables) HTML 101K
32: R29 Segments (Tables) HTML 156K
36: R30 Business and Organization (Details) HTML 46K
37: R31 Summary of Significant Accounting Policies HTML 61K
(Details)
39: R32 Loss Per Share (Details) HTML 36K
20: R33 Composition of Certain Financial Statement HTML 142K
Captions (Details)
68: R34 Composition of Certain Financial Statement HTML 67K
Captions - Changes in Goodwill (Details)
47: R35 Acquisitions, Investments, and Licenses - HTML 83K
Acquisition Narrative (Details)
49: R36 Acquisitions, Investments, and Licenses - Schedule HTML 68K
of Purchase Price Allocation (Details)
25: R37 Acquisitions, Investments, and Licenses - Schedule HTML 34K
of Pro Forma (Details)
79: R38 Acquisitions, Investments, and Licenses - Summary HTML 38K
of Investments (Details)
14: R39 Acquisitions, Investments, and Licenses - Equity HTML 52K
Method Investments Narrative (Details)
40: R40 Acquisitions, Investments, and Licenses - HTML 52K
Available for Sale Investments, Sale of
Investments and Warrants and Options Narrative
(Details)
73: R41 Acquisitions, Investments, and Licenses - HTML 48K
Pharmsynthez transactions Narrative (Details)
24: R42 Acquisitions, Investments, and Licenses - Variable HTML 55K
Interest Entities Narrative (Details)
31: R43 Acquisitions, Investments, and Licenses - Schedule HTML 86K
of Consolidated Assets and Non-Recourse
Liabilities (Details)
35: R44 Debt - Narrative (Details) HTML 106K
43: R45 Debt - Notes (Details) HTML 53K
19: R46 Debt - Inputs Used In Lattice Model (Details) HTML 43K
28: R47 Debt - Fair Value Of Embedded Derivatives HTML 31K
(Details)
16: R48 Debt - Lines Of Credit (Details) HTML 54K
72: R49 Debt - Mortgage Notes And Other Debt (Details) HTML 35K
23: R50 Accumulated Other Comprehensive Income (Loss) HTML 46K
(Details)
69: R51 Fair Value Measurements - Summary Of Investments HTML 43K
(Details)
26: R52 Fair Value Measurements - Assets And Liabilities HTML 68K
Measured At Fair Value (Details)
41: R53 Fair Value Measurements - Notes (Details) HTML 31K
15: R54 Fair Value Measurements - Level 3 Reconciliation HTML 39K
(Details)
18: R55 Fair Value Measurements - Narrative (Details) HTML 45K
34: R56 Derivative Contracts - Balance Sheet Component HTML 43K
(Details)
21: R57 Derivative Contracts - Derivative Gains (Losses) HTML 36K
(Details)
76: R58 Derivative Contracts - Outstanding Forward HTML 63K
Contracts (Details)
46: R59 Related Party Transactions (Details) HTML 135K
62: R60 Commitments and Contingencies (Details) HTML 39K
27: R61 Strategic Alliances (Details) HTML 69K
30: R62 Segments - Narrative (Details) HTML 52K
67: R63 Segments (Details) HTML 87K
66: R64 Subsequent Events (Details) HTML 48K
78: XML IDEA XML File -- Filing Summary XML 136K
17: EXCEL IDEA Workbook of Financial Reports XLSX 107K
8: EX-101.INS XBRL Instance -- opk-20150630 XML 3.06M
10: EX-101.CAL XBRL Calculations -- opk-20150630_cal XML 228K
11: EX-101.DEF XBRL Definitions -- opk-20150630_def XML 1.04M
12: EX-101.LAB XBRL Labels -- opk-20150630_lab XML 1.95M
13: EX-101.PRE XBRL Presentations -- opk-20150630_pre XML 1.26M
9: EX-101.SCH XBRL Schema -- opk-20150630 XSD 196K
44: ZIP XBRL Zipped Folder -- 0000944809-15-000011-xbrl Zip 309K
| OPK - 6.30.2015 - EX31.2 |
(1) | I have reviewed this Quarterly Report on Form 10-Q of OPKO Health, Inc.; |
(2) | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit
to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
(3) | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
(4) | The
registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
(a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
(b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
(c) | Evaluated the effectiveness of the
registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
(d) | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially
affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
(5) | The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
(a) | All
significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
(b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
Date:
August 5, 2015 | /s/ Adam Logal |
Senior Vice President, Chief Financial Officer, Chief Accounting Officer and Treasurer | |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 8/5/15 | 8-K | ||
| For Period end: | 6/30/15 | 4 | ||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/18/21 Opko Health, Inc. 10-K 12/31/20 111:16M |